hit counter
Ascendis Pharma A/S (ASND) Stock News Sentiment & Price - Sentifly
ASND - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Ascendis Pharma A/S (ASND)

Denmark
Biotechnology
NASDAQ
ASND Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ASND Latest news
GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
2021-10-15 08:00

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacies across the United States.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Share Repurchase Program
2021-09-29 16:01

COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company's American Depositary Shares (ADS) (the Share Repurchase Program), each of which represents one ordinary share of Ascendis Pharma A/S. The program will be executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
2021-09-22 16:27

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

Seeking Alpha
Positive
Ascendis Pharma: A Promising Platform And A Rich Valuation
2021-09-10 09:38

The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum of the parts figure based on the current pipeline assets.

Zacks Investment Research
Positive
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
2021-09-08 12:30

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Upcoming Investor Presentations
2021-09-07 17:09

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that the company will participate in two upcoming investor conferences. Company executives will provide a business overview and update on the company's programs.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ?/? Clinical Program
2021-09-07 16:59

– TransCon IL-2 ?/?  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2R?/?  with low C max –

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
2021-09-01 19:43

COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $160.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 375,000 ADSs at the public offering price, less the underwriting commissions.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
2021-08-31 16:01

COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Benzinga
Neutral
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
2021-08-31 14:00

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Loading more news...